These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 7036302)

  • 1. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
    El-Hage AN; Herman EH; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):509-23. PubMed ID: 7036302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
    el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of gamma-hydroxybutyrate on alloxan induced diabetes in mice.
    Pierrefiche G; Topall G; Henriet I; Laborit H
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):309-19. PubMed ID: 2047574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of protection from alloxan diabetes provided by n-butanol.
    Schauberger CW; Thies RL; Fischer LJ
    J Pharmacol Exp Ther; 1977 May; 201(2):450-5. PubMed ID: 323464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective effect of verapamil against alloxan-induced damage on pancreatic islet beta-cells in rats].
    Wei YJ; Yu GZ; Zhang GF; Yu JR
    Sheng Li Xue Bao; 1992 Apr; 44(2):209-14. PubMed ID: 1621112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against alloxan-induced diabetes by various urea derivatives: relationship between protective effects and reactivity with the hydroxyl radical.
    Tibaldi J; Benjamin J; Cabbat FS; Heikkila RE
    J Pharmacol Exp Ther; 1979 Nov; 211(2):415-8. PubMed ID: 501570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting the beta-cell sensitivity to alloxan in vivo. Influence of pre- and post-treatment with protective substances.
    Boquist L
    Acta Endocrinol (Copenh); 1978 Jul; 88(3):556-61. PubMed ID: 354301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metabolic alkalosis on the B-cell sensitivity to alloxan in vivo.
    Boquist L
    Horm Metab Res; 1978 Nov; 10(6):477-81. PubMed ID: 33888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against alloxan-induced diabetes by various dialkyldithiocarbamates.
    Masukawa T; Nakanishi K; Katakawa J; Tetsumi T
    Experientia; 1995 Jan; 51(1):29-31. PubMed ID: 7843327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro.
    Gai W; Schott-Ohly P; Schulte im Walde S; Gleichmann H
    Exp Clin Endocrinol Diabetes; 2004 Jan; 112(1):29-37. PubMed ID: 14758569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alloxan on the islets of Langerhans. Possible mechanisms of diabetogenic action.
    Borg LA
    Acta Biol Med Ger; 1981; 40(1):71-6. PubMed ID: 7020307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protective effect of glucose, but not 3-O-methyl glucose, against alloxan-induced diabetes depends upon the route of hexose administration.
    Jansson L; Sandler S
    Arch Int Pharmacodyn Ther; 1988; 293():257-64. PubMed ID: 3048222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
    Herman EH; Ferrans VJ; Jordan W; Ardalan B
    Res Commun Chem Pathol Pharmacol; 1981 Jan; 31(1):85-97. PubMed ID: 6789416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxan-induced diabetes in CD-1 mice.
    Ho E; Chen G; Bray TM
    FASEB J; 1999 Oct; 13(13):1845-54. PubMed ID: 10506589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activity of ICRF-159 combined with surgery: effects of postsurgical treatment with cyclophosphamide in mice bearing Lewis lung carcinoma lines.
    Sava G; Zorzet S; Perissin L
    Anticancer Res; 1985; 5(5):511-5. PubMed ID: 4062252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-arginine and polyamine administration protect beta-cells against alloxan diabetogenic effect in Sprague-Dawley rats.
    Méndez JD; Hernández Rde H
    Biomed Pharmacother; 2005 Jul; 59(6):283-9. PubMed ID: 15996850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.